Dr. Takara L. Stanley
Massachusetts General Hospital and Harvard Medical School
Biography & Research Background
Takara L. Stanley, MD, is at Massachusetts General Hospital and Harvard Medical School. She has conducted extensive research into the metabolic profile of Tesamorelin study subjects, including liver enzymes, inflammatory markers, and GH pulsatility. Her landmark Lancet HIV trial (2019) demonstrated Tesamorelin prevents hepatic fibrosis progression in NAFLD. Takara L. Stanley is being referenced as one of the leading scientists involved in the research and development of Tesamorelin. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Takara L. Stanley is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Takara L. Stanley is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.